IDH1 and central nervous system cancer: Glioma-related mutations have been linked to this increased VTE risk – the incidence is strikingly higher in patients with isocitrate dehydrogenase 1 (IDH1) wildtype tumors, which distinguishes glioblastomas from other gliomas [38].